Literature DB >> 14726996

Effect of ambient temperature and a prior neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA) on the hyperthermic response of rats to a single or repeated ('binge' ingestion) low dose of MDMA.

A Richard Green1, Veronica Sanchez, Esther O'Shea, Kathryn S Saadat, J Martin Elliott, M Isabel Colado.   

Abstract

RATIONALE: 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) administration to rats produces acute hyperthermia and long-term neurotoxic damage to 5-hydroxytryptamine (serotonin, 5-HT) neurones.
OBJECTIVE: We wished to examine MDMA-induced hyperthermia in rats housed at normal (19 degrees C) and high (30 degrees C) room temperatures and investigate the effect of a prior neurotoxic lesion.
METHODS: Rectal temperature was measured after administration of single or repeated doses of MDMA to rats housed at 19 degrees C and 30 degrees C.
RESULTS: MDMA (5 mg/kg i.p.) produced a sustained hyperthermic response in rats housed at 30 degrees C, but not in rats housed at 19 degrees C. A prior (5 weeks earlier) neurotoxic dose of MDMA (12.5 mg/kg i.p.) resulted in MDMA (5 mg/kg) producing a greater hyperthermic response in rats housed at 30 degrees C than in non-pre-treated animals. Repeated MDMA administration (binge dosing; 2, 4 or 6 mg/kg x3) produced dose-dependent hyperthermia in rats housed at 19 degrees C, with MDMA (2 mg/kg x3) having little effect. However, this dose produced significant hyperthermia (> or =2 degrees C above control values)in rats housed at 30 degrees C following the third dose. A prior neurotoxic dose of MDMA resulted in MDMA (2 mg/kg x3) producing marked hyperthermia (>1 degrees C) after the first dose and severe hyperthermia (> or =2 degrees C) after the third dose.
CONCLUSIONS: MDMA administration to rats housed at 30 degrees C produces a more severe hyperthermic response than that seen in rats housed at 19 degrees C. A prior neurotoxic dose enhances the response further in animals housed at 30 degrees C. Binge dosing produces a higher final peak response than a similar non-divided dose. This effect is more marked in animals housed at high room temperature. These data may have implications for recreational users of MDMA in hot environments, particularly those who may have damaged serotoninergic neurones because of prior heavy or frequent use of the drug.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14726996     DOI: 10.1007/s00213-003-1725-2

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  27 in total

1.  Factors influencing the toxicity of sympathomimetic amines to solitary mice.

Authors:  M R A CHANCE
Journal:  J Pharmacol Exp Ther       Date:  1947-03       Impact factor: 4.030

Review 2.  Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity.

Authors:  A C Parrott
Journal:  Pharmacol Biochem Behav       Date:  2002-04       Impact factor: 3.533

Review 3.  Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy').

Authors:  G A Ricaurte; U D McCann; Z Szabo; U Scheffel
Journal:  Toxicol Lett       Date:  2000-03-15       Impact factor: 4.372

4.  Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy")

Authors:  J A Henry; K J Jeffreys; S Dawling
Journal:  Lancet       Date:  1992-08-15       Impact factor: 79.321

5.  Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings.

Authors:  U D McCann; Z Szabo; U Scheffel; R F Dannals; G A Ricaurte
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

6.  The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy').

Authors:  E O'Shea; R Granados; B Esteban; M I Colado; A R Green
Journal:  Neuropharmacology       Date:  1998-07       Impact factor: 5.250

7.  Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA).

Authors:  W Slikker; S F Ali; A C Scallet; C H Frith; G D Newport; J R Bailey
Journal:  Toxicol Appl Pharmacol       Date:  1988-07       Impact factor: 4.219

8.  Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine.

Authors:  J F Nash; H Y Meltzer; G A Gudelsky
Journal:  J Pharmacol Exp Ther       Date:  1988-06       Impact factor: 4.030

9.  Changes in cardiovascular responsiveness and cardiotoxicity elicited during binge administration of Ecstasy.

Authors:  Lisa A Badon; Alissa Hicks; Kevin Lord; Brian A Ogden; Suzanne Meleg-Smith; Kurt J Varner
Journal:  J Pharmacol Exp Ther       Date:  2002-09       Impact factor: 4.030

10.  Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ('Ecstasy') to rats.

Authors:  K E Hewitt; A R Green
Journal:  Neuropharmacology       Date:  1994-12       Impact factor: 5.250

View more
  18 in total

1.  Acute concomitant effects of MDMA binge dosing on extracellular 5-HT, locomotion and body temperature and the long-term effect on novel object discrimination in rats.

Authors:  Ratchanee Rodsiri; Clare Spicer; A Richard Green; Charles A Marsden; Kevin C F Fone
Journal:  Psychopharmacology (Berl)       Date:  2010-07-20       Impact factor: 4.530

2.  3,4-Methylenedioxymethamphetamine in adult rats produces deficits in path integration and spatial reference memory.

Authors:  Jessica A Able; Gary A Gudelsky; Charles V Vorhees; Michael T Williams
Journal:  Biol Psychiatry       Date:  2005-12-01       Impact factor: 13.382

3.  MDMA: on the translation from rodent to human dosing.

Authors:  A Richard Green; Johan Gabrielsson; Charles A Marsden; Kevin C F Fone
Journal:  Psychopharmacology (Berl)       Date:  2009-01-13       Impact factor: 4.530

4.  Studies on the effect of MDMA ('ecstasy') on the body temperature of rats housed at different ambient room temperatures.

Authors:  A Richard Green; Esther O'Shea; Kathryn S Saadat; J Martin Elliott; M Isabel Colado
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

Review 5.  The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives.

Authors:  J R Docherty; A R Green
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

6.  Mechanisms and environmental factors that underlying the intensification of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-induced serotonin syndrome in rats.

Authors:  Rui Tao; Ibrahim M Shokry; John J Callanan; H Daniel Adams; Zhiyuan Ma
Journal:  Psychopharmacology (Berl)       Date:  2014-10-11       Impact factor: 4.530

7.  The role of 5-HT in the impairment of thermoregulation observed in rats administered MDMA ('ecstasy') when housed at high ambient temperature.

Authors:  Kathryn S Saadat; Esther O'shea; M Isabel Colado; J Martin Elliott; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2005-01-14       Impact factor: 4.530

Review 8.  Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans.

Authors:  A R Green; M V King; S E Shortall; K C F Fone
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

9.  Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart.

Authors:  A M Peiró; M Farré; P N Roset; M Carbó; M Pujadas; M Torrens; J Camí; R de la Torre
Journal:  Psychopharmacology (Berl)       Date:  2012-11-10       Impact factor: 4.530

10.  Distribution of temperature changes and neurovascular coupling in rat brain following 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") exposure.

Authors:  Daniel Coman; Basavaraju G Sanganahalli; Lihong Jiang; Fahmeed Hyder; Kevin L Behar
Journal:  NMR Biomed       Date:  2015-08-19       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.